000118854 001__ 118854 000118854 005__ 20240319081017.0 000118854 0247_ $$2doi$$a10.1186/s12951-022-01546-y 000118854 0248_ $$2sideral$$a130302 000118854 037__ $$aART-2022-130302 000118854 041__ $$aeng 000118854 100__ $$aHernández, Ángela-Patricia 000118854 245__ $$aComprehensive and systematic characterization of multi-functionalized cisplatin nano-conjugate: from the chemistry and proteomic biocompatibility to the animal model 000118854 260__ $$c2022 000118854 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118854 5203_ $$aBackground Nowadays, nanoparticles (NPs) have evolved as multifunctional systems combining different custom anchorages which opens a wide range of applications in biomedical research. Thus, their pharmacological involvements require more comprehensive analysis and novel nanodrugs should be characterized by both chemically and biological point of view. Within the wide variety of biocompatible nanosystems, iron oxide nanoparticles (IONPs) present mostly of the required features which make them suitable for multifunctional NPs with many biopharmaceutical applications. Results Cisplatin-IONPs and different functionalization stages have been broadly evaluated. The potential application of these nanodrugs in onco-therapies has been assessed by studying in vitro biocompatibility (interactions with environment) by proteomics characterization the determination of protein corona in different proximal fluids (human plasma, rabbit plasma and fetal bovine serum),. Moreover, protein labeling and LC–MS/MS analysis provided more than 4000 proteins de novo synthetized as consequence of the nanodrugs presence defending cell signaling in different tumor cell types (data available via ProteomeXchanges with identified PXD026615). Further in vivo studies have provided a more integrative view of the biopharmaceutical perspectives of IONPs. Conclusions Pharmacological proteomic profile different behavior between species and different affinity of protein coating layers (soft and hard corona). Also, intracellular signaling exposed differences between tumor cell lines studied. First approaches in animal model reveal the potential of theses NPs as drug delivery vehicles and confirm cisplatin compounds as strengthened antitumoral agents. 000118854 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00400$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PT17-0019-0023$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-01538$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-01930$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI21-01545 000118854 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000118854 590__ $$a10.2$$b2022 000118854 592__ $$a1.421$$b2022 000118854 591__ $$aNANOSCIENCE & NANOTECHNOLOGY$$b21 / 107 = 0.196$$c2022$$dQ1$$eT1 000118854 593__ $$aApplied Microbiology and Biotechnology$$c2022$$dQ1 000118854 591__ $$aBIOTECHNOLOGY & APPLIED MICROBIOLOGY$$b12 / 158 = 0.076$$c2022$$dQ1$$eT1 000118854 593__ $$aBioengineering$$c2022$$dQ1 000118854 593__ $$aBiomedical Engineering$$c2022$$dQ1 000118854 593__ $$aPharmaceutical Science$$c2022$$dQ1 000118854 593__ $$aMolecular Medicine$$c2022$$dQ1 000118854 593__ $$aNanoscience and Nanotechnology$$c2022$$dQ1 000118854 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1 000118854 594__ $$a10.0$$b2022 000118854 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118854 700__ $$aMicaelo, Ania 000118854 700__ $$0(orcid)0000-0001-7625-4806$$aPiñol, Rafael 000118854 700__ $$aGarcía-Vaquero, Marina L. 000118854 700__ $$0(orcid)0000-0002-5864-9211$$aAramayona, José J.$$uUniversidad de Zaragoza 000118854 700__ $$aCriado, Julio J. 000118854 700__ $$aRodriguez, Emilio 000118854 700__ $$aSánchez-Gallego, José Ignacio 000118854 700__ $$aLandeira-Viñuela, Alicia 000118854 700__ $$aJuanes-Velasco, Pablo 000118854 700__ $$aDíez, Paula 000118854 700__ $$aGóngora, Rafael 000118854 700__ $$aJara-Acevedo, Ricardo 000118854 700__ $$aOrfao, Alberto 000118854 700__ $$0(orcid)0000-0001-5981-5448$$aMiana-Mena, Javier$$uUniversidad de Zaragoza 000118854 700__ $$0(orcid)0000-0001-8301-6902$$aMuñoz, María Jesús$$uUniversidad de Zaragoza 000118854 700__ $$0(orcid)0000-0001-6209-4282$$aVillanueva, Sergio$$uUniversidad de Zaragoza 000118854 700__ $$0(orcid)0000-0003-0828-3212$$aMillán, Ángel 000118854 700__ $$aFuentes, Manuel 000118854 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología 000118854 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología 000118854 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Medicina y Cirugía Animal 000118854 773__ $$g20 (2022), 341 [19 pp.]$$pJ. nanobiotechnol.$$tJournal of Nanobiotechnology$$x1477-3155 000118854 8564_ $$s3687563$$uhttps://zaguan.unizar.es/record/118854/files/texto_completo.pdf$$yVersión publicada 000118854 8564_ $$s2229055$$uhttps://zaguan.unizar.es/record/118854/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118854 909CO $$ooai:zaguan.unizar.es:118854$$particulos$$pdriver 000118854 951__ $$a2024-03-18-15:49:36 000118854 980__ $$aARTICLE